Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments Centre

Lung cancer

Click on the title for more information (where available).

Onyimadu, O., Lord, J., Picot, J., Cooper, K., Scott, D., Shepherd, J., Atezolizumab in combination for treating advanced non-squamous non-small-cell lung cancer: A Single Technology Appraisal. Southampton Health Technology Assessments Centre (SHTAC), 2018.

Pickett K, Rose M, Colquitt J, Loveman E, Frampton G, Clegg A, Lord J. Necitumumab for untreated advanced, metastatic, squamous non-small-cell lung cancer: A Single Technology Appraisal. Southampton Health Technology Assessments Centre, 2015.

Hartwell D, Jones J, Loveman E, Harris P, Clegg A, and Bird A. Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation. Cancer Treatment Reviews 2011;37:242-249.

Loveman E, Jones J, Hartwell D, Bird A, Harris P, Welch K et al. The clinical and cost effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation. Health Technology Assessment 2010;4(19)

Clegg A, Scott D, Hewitson P, Sidhu M, Waugh N. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in lung cancer. Thorax 2002;57:20-8. 

Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N. Clinical and cost effectiveness of docetaxel, gemcitabine, paclitaxel and vinorelbine in lung cancer. Health Technology Assessment 2001;5(32).  

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×